Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage
Zilan Song, Bo Liu, Xia Peng, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 22, pp. 16687-16702
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Molecular glues for protein-protein interactions: Progressing toward a new dream
Markella Konstantinidou, Michelle R. Arkin
Cell chemical biology (2024) Vol. 31, Iss. 6, pp. 1064-1088
Open Access | Times Cited: 21
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Sadique A. Javed, Asim Najmi, Waquar Ahsan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 18
Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy
Qiaohong Geng, Peifu Jiao
Molecules (2024) Vol. 29, Iss. 2, pp. 454-454
Open Access | Times Cited: 6
Small-molecule modulators of tumor immune microenvironment
Jing Zhang, Jia Yu, Meijing Liu, et al.
Bioorganic Chemistry (2024) Vol. 145, pp. 107251-107251
Closed Access | Times Cited: 5
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 5
Advancements in drug discovery: integrating CADD tools and drug repurposing for PD-1/PD-L1 axis inhibition
Patrícia Sobral, T. Carvalho, Shiva Izadi, et al.
RSC Advances (2025) Vol. 15, Iss. 4, pp. 2298-2316
Open Access
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020-2024)
Qiaohong Geng, Juanjuan Xu, Cheng Du, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Photocatalytically switchable chemoselective difluoramidation of olefins for the synthesis of diversified difluoro-γ-lactams
Tian-Zheng Cao, Cai-Jian Nie, Jing Li, et al.
Chemical Communications (2025)
Closed Access
Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment
Hongyu Wu, Hong Yao, Chen He, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 9, pp. 3548-3566
Open Access | Times Cited: 23
Design, Synthesis, and Biological Evaluation of a Small-Molecule PET Agent for Imaging PD-L1 Expression
Liang Xu, Lixia Zhang, Beibei Liang, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 213-213
Open Access | Times Cited: 14
Inside PD-1/PD-L1,2 with their inhibitors
Nicolas Boisgerault, Philìppe Bertrand
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115465-115465
Open Access | Times Cited: 14
Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors
Tongfei Jing, Zhijing Zhang, Zhenghui Kang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 10, pp. 6811-6835
Closed Access | Times Cited: 13
Discovery and Crystallography Study of Novel Biphenyl Ether and Oxadiazole Thioether (Non-Arylmethylamine)-Based Small-Molecule PD-1/PD-L1 Inhibitors as Immunotherapeutic Agents
Jin Liu, Yao Cheng, L. Yuan, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 18, pp. 13172-13188
Closed Access | Times Cited: 13
Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy
Yongling Xu, Huijie Du, Weibo Guo, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 4083-4099
Closed Access | Times Cited: 4
Progress in small-molecule inhibitors targeting PD-L1
J. Xu, Yuanfang Kong, Pengbo Zhu, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 4, pp. 1161-1175
Closed Access | Times Cited: 4
Design, Synthesis, and Evaluation of PD-1/PD-L1 Antagonists Bearing a Benzamide Scaffold
Lu Lu, Zhihao Qi, Tianyu Wang, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 4, pp. 586-592
Open Access | Times Cited: 18
Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction
Pujan Sasmal, B. Sajeev Kumar, B. R. Prashantha Kumar, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 73, pp. 117001-117001
Closed Access | Times Cited: 18
Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2′-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors
Hua Zhang, Shijia Zhou, Jacek Plewka, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10579-10603
Closed Access | Times Cited: 11
Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors
Patrícia Sobral, Vanessa C. C. Luz, João M. G. C. F. Almeida, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5908-5908
Open Access | Times Cited: 10
Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy
Zichao Yang, Ziqing Liu, Shanhe Wan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 7995-8019
Closed Access | Times Cited: 3
Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction
Raphaël Le Biannic, Romain Magnez, Frédérique Klupsch, et al.
European Journal of Medicinal Chemistry (2022) Vol. 236, pp. 114343-114343
Open Access | Times Cited: 17
Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function
Wei Zou, Xin Luo, Mengyuan Gao, et al.
British Journal of Pharmacology (2023) Vol. 181, Iss. 2, pp. 257-272
Open Access | Times Cited: 8
Discovery of Novel Non-Nucleoside Inhibitors Interacting with Dizinc Ions of CD73
Cunjian Shi, Longfeng Chang, Jie Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 11, pp. 9686-9708
Closed Access | Times Cited: 2
Discovery of small-molecule PD-1/PD-L1 antagonists through combined virtual screening and experimental validation
Michelle DiFrancesco, Jeremy Hofer, Abhay G. Aradhya, et al.
Computational Biology and Chemistry (2022) Vol. 102, pp. 107804-107804
Closed Access | Times Cited: 12
Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D Inhibitors
Xuanzheng Xiao, Juanjuan Feng, Jing Ma, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 22, pp. 15524-15549
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top